The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Abstract
Mutation in p53 is the most frequent event in cancer development and a leading cause of cancer therapy resistance due to evasion of the apoptosis cascade. Beyond chemotherapies and radiation therapies, growing evidence indicates that p53-mutant tumors are resistant to a broad range of immune-based therapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T, and hematopoietic stem cell transplantation (HSCT). This highlights the role of p53 mutations in driving immune evasion of tumor cells. In this review, we first summarize recent studies revealing mechanisms by which p53-mutant tumors evade immune surveillance from T cells, natural killer (NK) cells, and macrophages. We then review how these mutant tumor cells reshape the tumor microenvironment (TME), modulating bystander cells such as macrophages, neutrophils, and regulatory T (Treg) cells to foster immunosuppression. Additionally, we review clinical observations indicative of immune evasion associated with p53 loss or mutations. Finally, we discuss therapeutic strategies to enhance immune response in p53 wild-type (WT) or mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A critical mechanism driving TP53-mutation-associated cancers involve disrupted tumor microenvironment (TME) communication driven by cytokine secretion from cancer cells 47.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“1) clinical outcomes, frequently heralding a dismal prognosis [12].”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“Mitochondrial apoptosis is regulated by a series of pro-apoptotic and anti-apoptotic proteins in the mitochondria. p53 is known to induce the expression of pro-apoptotic proteins Noxa [58], Bax [59], and Puma [6], thus making tumor cells more primed to mitochondrial apoptosis.”
BackgroundImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625 · cited 1×
“They can also upregulate immune checkpoints and soluble immunosuppressive molecules to contribute to evasion from T cells [47].”
BackgroundTargeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441 · cited 2×
“Hsiue et al. developed a bispecific antibody that targets p53 R175H presented by HLA-A*02:01 on one arm and CD3 on the other arm to engage T cells to kill tumor cells [97].”
Background
Research works printed but not linked: 82
- Ge, 2022, Crosstalk between metabolic reprogramming and epigenetics in cancer: Updates on mechanisms and therapeutic opportunities, Cancer Commun., 42, 1049, 10.1002/cac2.12374 · DOI · Paper page
- Zhang, 2018, Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases, Nat. Commun., 9, 3953, 10.1038/s41467-018-06146-9 · DOI
- Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin. Cancer Res., 12, 1157, 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
- Lane, 1992, p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
- Vogelstein, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
- Brady, 2011, Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression, Cell, 145, 571, 10.1016/j.cell.2011.03.035 · DOI · Paper page
- Rivlin, 2011, Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889 · DOI · Paper page
- Roszkowska, K.A., Piecuch, A., Sady, M., Gajewski, Z., and Flis, S. (2022). Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches. Int. J. Mol. Sci., 23. · DOI
- Alvarado-Ortiz, E., de la Cruz-López, K.G., Becerril-Rico, J., Sarabia-Sánchez, M.A., Ortiz-Sánchez, E., and García-Carrancá, A. (2021). Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front. Cell Dev. Biol., 8. · DOI · Paper page
- Geske, 2000, DNA repair is activated in early stages of p53-induced apoptosis, Cell Death Differ., 7, 393, 10.1038/sj.cdd.4400663 · DOI
- Zhu, K.-L., Su, F., Yang, J.-R., Xiao, R.-W., Wu, R.-Y., Cao, M.-Y., Ling, X.-L., and Zhang, T. (2024). TP53 to mediate immune escape in tumor microenvironment: An overview of the research progress. Mol. Biol. Rep., 51. · DOI
- Zhou, 2022, Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246, Br. J. Cancer, 127, 2060, 10.1038/s41416-022-01971-8 · DOI
- Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
- Saha, 2013, Targeting p53 by small molecules in hematological malignancies, J. Hematol. Oncol., 6, 23, 10.1186/1756-8722-6-23 · DOI
- Malekzadeh, 2019, Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers, J. Clin. Investig., 129, 1109, 10.1172/JCI123791 · DOI · Paper page
- Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
- Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
- Lepre, M.G., Omar, S.I., Grasso, G., Morbiducci, U., Deriu, M.A., and Tuszynski, J.A. (2017). Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA. Molecules, 22. · DOI
- Pintus, 2013, The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain, J. Biomol. Struct. Dyn., 31, 78, 10.1080/07391102.2012.691364 · DOI
- Balasundaram, A., and Doss, C.G.P. (2022). Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach. Int. J. Mol. Sci., 23. · DOI · Paper page
- Klemke, L., Fehlau, C.F., Winkler, N., Toboll, F., Singh, S.K., Moll, U.M., and Schulz-Heddergott, R. (2021). The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells. Front. Oncol., 11. · DOI
- Wang, 2019, It takes a team: A gain-of-function story of p53-R249S, J. Mol. Cell Biol., 11, 277, 10.1093/jmcb/mjy086 · DOI
- Zhang, J., Liu, M., Fang, Y., Li, J., Chen, Y., and Jiao, S. (2022). TP53 R273C Mutation Is Associated with Poor Prognosis in LGG Patients. Front. Genet., 13. · DOI
- Garg, 2019, Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties, Biophys. J., 118, 720, 10.1016/j.bpj.2019.12.015 · DOI
- Calhoun, 2011, Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain, Biochemistry, 50, 5345, 10.1021/bi200192j · DOI
- Zhang, 2017, TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer, Diagn. Pathol., 12, 16, 10.1186/s13000-017-0605-8 · DOI
- Kucab, 2010, Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model, FEBS J., 277, 2567
- Guha, 2017, Inherited TP53 Mutations and the Li-Fraumeni Syndrome, Cold Spring Harb. Perspect. Med., 7, a026187, 10.1101/cshperspect.a026187 · DOI · Paper page
- Zanier, 2016, HPV-mediated inactivation of tumor suppressor p53, Cell Cycle, 15, 2231, 10.1080/15384101.2016.1191257 · DOI
- Zong, 2024, Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis, Cell, 187, 2375, 10.1016/j.cell.2024.04.002 · DOI · Paper page
- Wang, 2013, p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1, Nat. Commun., 4, 2359, 10.1038/ncomms3359 · DOI
- Izquierdo, 2022, Extracellular vesicles and PDL1 suppress macrophages inducing therapy resistance in TP53-deficient B-cell malignancies, Blood, 139, 3617, 10.1182/blood.2021014007 · DOI
- Efe, 2023, p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression, Cancer Discov., 13, 2632, 10.1158/2159-8290.CD-23-0601 · DOI
- Siolas, 2021, Gain-of-function p53(R172H) mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy, Cell Rep., 36, 109578, 10.1016/j.celrep.2021.109578 · DOI
- Cooks, 2018, Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246, Nat. Commun., 9, 771, 10.1038/s41467-018-03224-w · DOI · Paper page
- Ghosh, 2021, Mutant p53 suppresses innate immune signaling to promote tumorigenesis, Cancer Cell, 39, 494, 10.1016/j.ccell.2021.01.003 · DOI · Paper page
- Martin, 2021, The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation, Science, 373, 1327, 10.1126/science.abg5784 · DOI
- Aptsiauri, 2022, The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes, Clin. Cancer Res., 28, 5021, 10.1158/1078-0432.CCR-21-3501 · DOI
- Zhu, 1999, p53 induces TAP1 and enhances the transport of MHC class I peptides, Oncogene, 18, 7740, 10.1038/sj.onc.1203235 · DOI
- Ho, 2022, Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation, Blood, 140, 1167, 10.1182/blood.2022016082 · DOI
- Schmaltz, 2002, T cells require TRAIL for optimal graft-versus-tumor activity, Nat. Med., 8, 1433, 10.1038/nm1202-797 · DOI · Paper page
- Costa, 2020, P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma, Cell Death Dis., 11, 748, 10.1038/s41419-020-02940-w · DOI
- Langenbach, 2023, MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production, Mol. Cancer Res., 21, 849, 10.1158/1541-7786.MCR-22-0898 · DOI
- Winter, 2023, The Battle within: AML´s p53 Strategies to Evade T-Cell Attack, Blood, 142, 1411, 10.1182/blood-2023-173826 · doi:10.1182/blood-2023-173826
- Liao, 1991, MHC Class I Deficiency: Susceptibility to Natural Killer (NK) Cells and Impaired NK Activity, Science, 253, 199, 10.1126/science.1853205 · DOI · Paper page
- Wolf, 2022, Roles of natural killer cells in immunity to cancer, and applications to immunotherapy, Nat. Rev. Immunol., 23, 90, 10.1038/s41577-022-00732-1 · DOI · Paper page
- Veneziani, 2021, Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors, Cancer Immunol. Res., 9, 170, 10.1158/2326-6066.CIR-20-0313 · DOI
- Pan, 2022, Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis, Cell, 185, 1521, 10.1016/j.cell.2022.03.030 · DOI · Paper page
- Weiskopf, 2015, Macrophages are critical effectors of antibody therapies for cancer, mAbs, 7, 303, 10.1080/19420862.2015.1011450 · DOI · Paper page
- Zhang, 2014, The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop, Cell Rep., 6, 421, 10.1016/j.celrep.2014.01.003 · DOI · Paper page
- Blagih, 2020, Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses, Cell Rep., 30, 481, 10.1016/j.celrep.2019.12.028 · DOI · Paper page
- Onkar, 2022, The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes, Cancer Discov., 13, 23, 10.1158/2159-8290.CD-22-0475 · DOI · Paper page
- Christofides, 2022, The complex role of tumor-infiltrating macrophages, Nat. Immunol., 23, 1148, 10.1038/s41590-022-01267-2 · DOI · Paper page
- Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat. Med., 19, 1423, 10.1038/nm.3394 · DOI · Paper page
- Li, 2014, A unique role for p53 in the regulation of M2 macrophage polarization, Cell Death Differ., 22, 1081, 10.1038/cdd.2014.212 · DOI · Paper page
- Paluskievicz, C.M., Cao, X., Abdi, R., Zheng, P., Liu, Y., and Bromberg, J.S. (2019). T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Front. Immunol., 10. · DOI · Paper page
- Yang, 2012, TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma, Cancer Cell, 22, 291, 10.1016/j.ccr.2012.07.023 · DOI · Paper page
- Abolhalaj, 2022, Transcriptional profiling demonstrates altered characteristics of CD8(+) cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia, Cancer Med., 11, 3023, 10.1002/cam4.4661 · DOI
- Shouval, 2022, Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy, J. Clin. Oncol., 40, 369, 10.1200/JCO.21.02143 · DOI
- Zhang, 2021, Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study, Cancer Med., 10, 3165, 10.1002/cam4.3763 · DOI
- Middeke, 2016, TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation, Br. J. Haematol., 172, 914, 10.1111/bjh.13912 · DOI
- Ando, 2023, Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study), Br. J. Cancer, 129, 1032, 10.1038/s41416-023-02378-9 · DOI
- Wang, 2021, PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab, Lung Cancer, 151, 76, 10.1016/j.lungcan.2020.11.006 · DOI
- Carlisle, 2018, Impact of TP53 mutations on efficacy of PD-1 targeted immunotherapy in non-small cell lung cancer (NSCLC), J. Clin. Oncol., 36, e21090, 10.1200/JCO.2018.36.15_suppl.e21090 · doi:10.1200/jco.2018.36.15_suppl.e21090
- Zhu, 2023, Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden, Cancer Cell, 41, 1731, 10.1016/j.ccell.2023.09.006 · DOI · Paper page
- Kim, 2023, TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors, Cancer Med., 12, 12438, 10.1002/cam4.5953 · DOI · Paper page
- Vadakekolathu, 2020, TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML, Blood Adv., 4, 5011, 10.1182/bloodadvances.2020002512 · DOI
- Nag, 2013, The MDM2-p53 pathway revisited, J. Biomed. Res., 27, 254, 10.7555/JBR.27.20130030 · DOI · Paper page
- Hassin, 2022, Drugging p53 in cancer: One protein, many targets, Nat. Rev. Drug Discov., 22, 127, 10.1038/s41573-022-00571-8 · DOI · Paper page
- McKean, 2022, Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors, J. Clin. Oncol., 40, 9517, 10.1200/JCO.2022.40.16_suppl.9517 · DOI
- Focaccetti, C., Benvenuto, M., Pighi, C., Vitelli, A., Napolitano, F., Cotugno, N., Fruci, D., Palma, P., Rossi, P., and Bei, R. (2022). DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: A proof-of-concept study. Front. Immunol., 13. · DOI
- Roshandel, 2022, Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors, Health Sci. Rep., 5, e536, 10.1002/hsr2.536 · DOI
- Amouzegar, A., Chelvanambi, M., Filderman, J.N., Storkus, W.J., and Luke, J.J. (2021). STING Agonists as Cancer Therapeutics. Cancers, 13. · DOI · Paper page
- Diepstraten, 2024, Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers, Cancer Cell, 42, 850, 10.1016/j.ccell.2024.04.004 · DOI
- Park, 2022, Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors, ESMO Open, 7, 100573, 10.1016/j.esmoop.2022.100573 · DOI
- Xiao, 2024, Characterization of the generic mutant p53-rescue compounds in a broad range of assays, Cancer Cell, 42, 325, 10.1016/j.ccell.2024.01.008 · DOI
- Kim, 2018, Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor, OncoImmunology, 7, e1484982, 10.1080/2162402X.2018.1484982 · DOI
- Leung, 2021, A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer, J. Clin. Oncol., 39, 413, 10.1200/JCO.2021.39.15_suppl.4139 · DOI
- Lo, 2019, Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer, Cancer Immunol. Res., 7, 534, 10.1158/2326-6066.CIR-18-0686 · DOI · Paper page
- Kim, 2022, Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors, Cancer Immunol. Res., 10, 932, 10.1158/2326-6066.CIR-22-0040 · DOI · Paper page
- Cui, Y., and Guo, G. (2016). Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. Int. J. Mol. Sci., 17. · DOI
- Jaiswal, 2020, Clonal hematopoiesis and nonhematologic disorders, Blood, 136, 1606
Cited by
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Metadata
- Authors
- Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S.
- Affiliations
- Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore
- Duke-NUS Medical School, Singapore 169857, Singapore
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-09-03
- Volume
- 16
- Issue
- 17
- Pages
- 3069
- ISSN
- 2072-6694
- Cited by
- 68
- References
- 19
- Language
- en
- Funders
- Paris-NUS Call (ANR-18-IDEX-0001)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. https://app.cochat.ai/papers/10.3390/cancers16173069
- The paper
- Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024). TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications. Cancers. https://doi.org/10.3390/cancers16173069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.